Vimpat
Product Images NDC 54868-6077

4 FDA label images from Physicians Total Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Vimpat (NDC 54868-6077). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

Principal Display Panel (50 mg Tablet Bottle Label)
The image shows a drug label for Vimpat 50mg tablets, distributed by Physicians Total Care, Inc. in Tulsa, Oklahoma, with product NDC 54868-6077. It includes a lot number and an expiration date, along with a barcode and the manufacturer identified as UCB Pharma, Inc.*
FDA Label Image

Chemical Structure (Vimpat 01)

Chemical Structure (Vimpat 01)
Chemical structure of the active ingredient in Vimpat, showing its molecular arrangement with functional groups, including a benzyl group, amide linkages, and keto groups. The diagram depicts the atom connectivity typical for this pharmaceutical compound.*
FDA Label Image

Figure (Vimpat 02)

Figure (Vimpat 02)
A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' for Vimpat. It compares seizure reduction percentages for placebo and different Vimpat doses across three studies, showing statistically significant greater reductions with Vimpat doses. The vertical axis represents median percent seizure reduction.*
FDA Label Image

Figure (Vimpat 03)

Figure (Vimpat 03)
A line graph titled 'Proportion of Patients by Responder Rate for VIMPAT and Placebo Groups in Studies 1, 2, and 3' showing responder rates over percent of patients. The graph compares placebo to VIMPAT doses of 200 mg/day, 400 mg/day, and 600 mg/day, with responder rate (equal to or greater) on the vertical axis and percent of patients on the horizontal axis. Four distinct lines represent each group with varying patient numbers (N values).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.